13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001907884
Total reported value
$1.8B
$1.8B
32 檔
31.8%
During the Q1 2025 filing period, Kynam Capital Management, LP (CIK: 0001907884) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.8B across 32 reported positions.
In Q1 2025, Kynam Capital Management, LP displayed an active expansion posture, initiating 6 new positions and adding to 14 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | Stock-Healthcare | 13.87% | — | -42.26% | |
| 2 | PCVX | Vaxcyte Inc | Stock-Other | 10.15% | -1.09% | +36.94% | |
| 3 | CLDX | Celldex Therapeutics Inc | Stock-Other | 9.91% | -0.48% | +28.35% | |
| 4 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 8.79% | -1.87% | — | |
| 5 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 5.63% | -1.95% | -1.73% | |
| 6 | CGON | Cg Oncology Inc | Stock-Other | 5.37% | — | +3.65% | |
| 7 | VRDN | Viridian Therapeutics Inc | Stock-Other | 5.32% | +3.72% | +41.30% | |
| 8 | VERA | Vera Therapeutics Inc | Stock-Other | 4.84% | -1.58% | +64.62% | |
| 9 | COGT | Cogent Biosciences Inc | Stock-Other | 4.58% | -1.75% | — | |
| 10 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 4.23% | +0.76% | +38.35% | |
| 11 | BEAM | Beam Therapeutics Inc | Stock-Other | 4.13% | -0.02% | +43.39% | |
| 12 | WVE | Wave Life Sciences Ltd. | Stock-Other | 3.33% | -0.43% | EXIT | |
| 13 | DVAX | Dynavax Technologies CORP | Stock-Other | 2.86% | — | -60.05% | |
| 14 | TVTX | Travere Therapeutics Inc | Stock-Other | 2.71% | +1.84% | — | |
| 15 | TYRA | Tyra Biosciences Inc | Stock-Other | 1.88% | — | +353.57% | |
| 16 | ✓ | Engene Holdings Inc | Stock-Other | 1.88% | -0.57% | EXIT | |
| 17 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.82% | -1.16% | EXIT | |
| 18 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.74% | +3.03% | — | |
| 19 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 1.49% | +0.40% | +86.68% | |
| 20 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.80% | +0.46% | — | |
| 21 | LQDA | Liquidia CORP | Stock-Other | 0.79% | — | -72.03% | |
| 22 | IRWD | Ironwood Pharmaceuticals Inc | Stock-Other | 0.72% | — | +24.27% | |
| 23 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.67% | +2.54% | +206.33% | |
| 24 | GERN | Geron CORP | Stock-Other | 0.49% | -0.15% | — | |
| 25 | ✓ | Amarin Corp PLC | Stock-Other | 0.47% | — | — | |
| 26 | BNR | Burning Rock Biotech Ltd-adr | Stock-Other | 0.37% | -0.64% | — | |
| 27 | STRO | Sutro Biopharma, Inc. | Stock-Other | 0.30% | — | +49.43% | |
| 28 | DSGN | Design Therapeutics Inc | Stock-Other | 0.29% | -0.52% | EXIT | |
| 29 | CRBU | Caribou Biosciences Inc | Stock-Other | 0.25% | -0.05% | +35.87% | |
| 30 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.20% | — | — | |
| 31 | CLYM | Climb Bio Inc | Stock-Other | 0.11% | -0.42% | EXIT | |
| 32 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.02% | +2.46% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CLDX | Celldex Therapeutics Inc | +2.4% | +28.35% | Add |
| 2 | SNDX | Syndax Pharmaceuticals Inc | +2.1% | — | Unchanged |
| 3 | IMCR | Immunocore Holdings Plc-adr | +2.1% | +38.35% | Add |
| 4 | SLNOEUR | Soleno Therapeutics Inc | +1.8% | NEW | New buy |
| 5 | LEGN | Legend Biotech Corp-adr | +1.7% | NEW | New buy |
| 6 | BCRX | Biocryst Pharmaceuticals Inc | +1.6% | -1.73% | Trim |
| 7 | BEAM | Beam Therapeutics Inc | +1.6% | +43.39% | Add |
| 8 | VRDN | Viridian Therapeutics Inc | +1.6% | +41.30% | Add |
| 9 | TYRA | Tyra Biosciences Inc | +1.4% | +353.57% | Add |
| 10 | VERA | Vera Therapeutics Inc | +1.2% | +64.62% | Add |
| 11 | CGON | Cg Oncology Inc | +1.1% | +3.65% | Add |
| 12 | TVTX | Travere Therapeutics Inc | +0.9% | — | Unchanged |
| 13 | NRIX | Nurix Therapeutics Inc | +0.8% | NEW | New buy |
| 14 | CGEM | Cullinan Therapeutics Inc | +0.6% | +86.68% | Add |
| 15 | GERN | Geron CORP | +0.5% | NEW | New buy |
| 16 | RLAY | Relay Therapeutics Inc | +0.4% | +206.33% | Add |
| 17 | COGT | Cogent Biosciences Inc | +0.4% | — | Unchanged |
| 18 | DSGN | Design Therapeutics Inc | +0.3% | NEW | New buy |
| 19 | ✓ | Amarin Corp PLC | +0.1% | — | Unchanged |
| 20 | CLYM | Climb Bio Inc | +0.1% | +91.41% | Add |
| 21 | CRBU | Caribou Biosciences Inc | 0% | +35.87% | Add |
| 22 | URGN | UroGen Pharma Ltd. | 0% | NEW | New buy |
| 23 | BNR | Burning Rock Biotech Ltd-adr | 0% | — | Unchanged |
| 24 | ✓ | Proqr Therapeutics N.v. | -0.1% | — | Unchanged |
| 25 | ✓ | Engene Holdings Inc | -0.1% | — | Unchanged |
| 26 | STRO | Sutro Biopharma, Inc. | -0.1% | +49.43% | Add |
| 27 | ✓ | Acelyrin Inc | -0.2% | EXIT | Sold out |
| 28 | WVE | Wave Life Sciences Ltd. | -0.3% | — | Unchanged |
| 29 | IRWD | Ironwood Pharmaceuticals Inc | -0.5% | +24.27% | Add |
| 30 | LQDA | Liquidia CORP | -0.8% | -72.03% | Trim |
| 31 | PTGX | Protagonist Therapeutics Inc | -0.9% | EXIT | Sold out |
| 32 | TSVT* | 2seventy Bio Inc | -1% | EXIT | Sold out |
| 33 | PCVX | Vaxcyte Inc | -1.2% | +36.94% | Add |
| 34 | DVAX | Dynavax Technologies CORP | -2.1% | -60.05% | Trim |
| 35 | NTRA | Natera Inc | -5.1% | -42.26% | Trim |
| 36 | SPY | Ss Spdr S&p 500 ETF Trust-us | -10.4% | EXIT | Sold out |
According to official SEC Form 13F filings, Kynam Capital Management, LP reported a total U.S. public equity portfolio value of $1.8B across 32 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NTRA, PCVX, CLDX) accounted for 31.8% of total reported equity market value during Q1 2025.
Top New Position Initiated
SLNOEUR
市值: $21.6M
Top Position Liquidated / Trimmed
SPY
前期市值: $175.8M
During Q1 2025, Kynam Capital Management, LP's top holdings by market value included NTRA (13.9%)、PCVX (10.2%)、CLDX (9.9%). The largest single position, NTRA, represented 13.9% of total portfolio value.
In Q1 2025, Kynam Capital Management, LP made 28 total portfolio adjustments, initiating 6 new buys, adding to 14 positions, trimming 4 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.